Pancreatic Cancer Collective New Therapies Challenge (an initiative of the Lustgarten Foundation and Stand Up To Cancer)
ABOUT THE PANCREATIC CANCER COLLECTIVE
The Pancreatic Cancer Collective (PCC) is an initiative of the Lustgarten Foundation and Stand Up To Cancer to improve pancreatic cancer patient outcomes. The Pancreatic Cancer Collective will accelerate research for pancreatic cancer patients who desperately need better treatments. Through the collective, these two leading organizations in the cancer community, with input from thought leaders, will create a dynamic and fluid network to engage and influence medical institutions, researchers and companies, aligned to achieve something bigger and more meaningful. For more information, visit www.pancreaticcancercollective.org
PROGRAM MISSION STATEMENT
The Pancreatic Cancer Collective New Therapies Challenge represents a new, focused effort to increase the number of innovative and effective therapies to treat pancreatic cancer by support of pre-clinical and clinical development efforts. The Pancreatic Cancer Collective, a strategic collaboration of the Lustgarten Foundation and Stand Up To Cancer, will support collaborative, and multi-disciplinary teams to investigate novel or repurposed medicines, treatment strategies or technologies that have the potential to significantly impact pancreatic cancer patients in the near term. The New Therapies Challenge involves a two-step approach that will provide initial, short-term funding to a number of applicants (Round 1), followed by additional funding for a subset of Round 1-funded teams (Round 2) for clinical studies. More details on the two rounds are as follows:
- The first round of funding will support studies to evaluate a novel or repurposed medicine, treatment strategy or technology for use in pancreatic cancer treatment.
- Proposed studies will contain clear milestones for success and culminate in a plan and/or approval for clinical testing.
- $1 million awards with a 14-month term will be provided to successful applicants.
- Awardees will be asked to execute contracts and sub-contracts by November 1, 2018.
- Awardees will be required to submit a written progress report, and a proposal for Round 2 funding 10 months after the beginning of the grant term.
- The second round of funding will support clinical studies of the most promising teams from Round 1.
- Proposed studies will contain milestones and deliverables, including a clinical trial enrollment strategy designed to fully accrue any trials by the end of the grant term.
- $4 million awards with a three-year term will be provided to successful applicants.
- The composition of the selected teams in Round 1, may be expanded for Round 2 to include additional expertise.
- Teams will be required to submit scientific progress reports and may be required to attend an in-person review meeting every six months throughout the grant term.
- Teams will be required to submit a monthly clinical trial report for all open trials.
To maximize creativity, innovation, and collaboration, the Team must be multi-disciplinary. Team members must demonstrate relevant clinical, translational, chemical and/or drug development expertise.
For Round 1, each team will consist of a team leader, one or two co-leaders, and a project manager.
For Round 2, each team will consist of a team leader, at least one of the co-Leaders in the Round 1-funded team, a project manager, and at least one advocate.
The team leader, co-leader, principals, project manager, and advocates are collectively referred to as Key Personnel. The team leader, co-leader and principals, must have acquired a doctoral or medical degree, and must be independent investigators affiliated with an academic, medical, or research institution. The designated project manager must belong to the team leader's institution.
The team leader and co-leader are expected to each dedicate at least 20 percent (or 40 percent combined) of their time and effort to the research project. Principals must each dedicate at least 10 percent of their time and effort to the research project.
Each team must designate a leader and co-leader who would preferably be from different institutions, and a project manager from the leader's institution.
At least one co-leader of the team must not be currently receiving grant support from SU2C or the Lustgarten Foundation.
Teams may collaborate with currently funded SU2C or Lustgarten Foundation teams to leverage existing expertise and resources. Efforts from these teams will be supported as supplemental awards to their existing grant. Employees or subcontractors of for-profit industry are not eligible to serve as a team leader, co-leader, or principal. However their participation as collaborators is encouraged, where appropriate, to foster the development of novel diagnostic and treatment strategies. No grant funds may be directly awarded to collaborators or any other individual working within a U.S. government institution/agency or a for-profit industry. Confidentiality and intellectual property issues must be negotiated with collaborators prior to their participation in the research project.
Young Investigators, including junior faculty, postdoctoral fellows, clinical research fellows, or any other researchers working under the direction of a scientific mentor, are not eligible to serve as a team leader, co-leader, or principal; however, their participation in the research project is encouraged.
There are no citizenship or residency status restrictions. Neither members of the PCC Joint Scientific Advisory Committee (JSAC) nor members of their individual laboratories are eligible for funding as part of the New Therapies Challenge Grant. At least one co-leader of the team must not be currently receiving grant support from SU2C or the Lustgarten Foundation. Teams may collaborate with currently funded SU2C or Lustgarten Foundation Teams to leverage existing expertise and resources. Efforts from these teams will be supported as supplemental awards to their existing grant.
Candidates with a question about the eligibility requirements are encouraged to contact the AACR's SRGA at email@example.com prior to submitting the proposal.
There are no citizenship or residency status restrictions.
The AACR requires applicants to submit an electronic Expression of Intent via proposalCENTRAL by 12:00 p.m. (noon), Eastern Time on Friday, June 1, 2018, using the proposalCENTRAL website at https://proposalcentral.altum.com
Using the Expression of Intent template provided in proposalCENTRAL, the team leader is asked to furnish the names of the team leader and co-leader/s, and the title of the proposed research project. Any team who does not upload an Expression of Intent form by the deadline will not be eligible to submit a Full Proposal. Once you have uploaded the form, we suggest that you take a screen shot of the webpage in proposalCENTRAL that states that your form has been successfully submitted, and keep this confirmation for your records. In addition to submitting the form on proposalCENTRAL, you may also email your Expression of Intent form directly to firstname.lastname@example.org. After you have accomplished this step, you can proceed to the submission of your proposal anytime before the stated deadline.